Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBImmunotherapy Instills Renewed Promise in SCLC. By Tony Berberabe, MPH. September 26th 2024. With immunotherapy-based regimens and novel agents like bispecific antibodies and antibody-drug conjugates, oncologist David R. Spigel, MD, is optimistic about the future of small cell lung cancer treatment.
Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets …
WEBAug 16, 2024 · The pivotal phase 3 inMIND trial (NCT04680052) of tafasitamab-cxix (Monjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody in combination with lenalidomide (Revlimid) and rituximab (Rituxan) vs lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma (FL) met its …
News - Targeted Oncology
WEBFDA Grants FTD to EO-3021 in Advanced Gastric and GEJ Cancers Expressing Claudin 18.2. Jordyn Sava. September 23rd 2024. The FDA granted fast track designation to EO-3021 for the treatment of advanced or metastatic gastric and gastroesophageal junction cancers expressing Claudin 18.2, which have progressed after prior therapy.
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE …
FDA Grants Breakthrough Therapy Designation to Vorasidenib …
WEBJun 15, 2020 · The Oncomine Precision Assay has been granted a Breakthrough Therapy Designation by the FDA to detect isocitrate dehydrogenase (IDH) 1 and 2 mutations in patients with low-grade glioma who may be eligible for treatment with vorasidenib (AG-881), a first-in-class IDH1/IDH2 inhibitor, announced Thermo Fisher Scientific. 1 "Access to …
FDA Acknowledges BLA of Zolbetuximab in HER2–, CLDN18.2
WEBMay 31, 2024 · The FDA has acknowledged the resubmitted biologics license application (BLA) for zolbetuximab (Vyloy) as a first-line treatment for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive. Zolbetuximab is a first-in-class …
Authors - Targeted Oncology
WEBCase 3: Role of Preoperative Endocrine Therapy in HR+ High-Risk Breast Cancer. Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer. Tina Cascone, MD, PhD.
Targeting STK11 Mutations in Cancer - Targeted Oncology
WEBJan 29, 2022 · David R. Gandara, MD. STK11 mutation recently have become a biomarker and potential target of interest, especially for patients with lung cancer. Recent trials explore drugs like bemcentinib, everolimus, talazoparib, and others for potential approaches to targeting these mutations.
Genetic Testing Empowers Better Cancer Care, Prevention, and …
WEBAug 13, 2021 · Preventing Cancer, Not Just Treating It. Although germline genetic testing can play a key role in the treatment of certain cancers, at the current time it plays an even more important role in the prevention or early detection of cancer. It is the goal of oncologists to not only provide high-quality cancer care, but also ultimately to prevent ...
Limited Treatment Options in nccRCC Expanding With IO/TKI …
WEBDec 12, 2023 · THE AVAILABILITY OF data for treatments of patients with clear cell renal cell carcinoma (ccRCC) dominates the field of therapeutics for these patients, as most patients with RCC will have ccRCC.However, according to the American Cancer Society, about 20% of patients with RCC will have non–ccRCC (nccRCC) with histology that …